Cure My Disease

Don't miss your cure!

 Log in / Sign up

Designer cells aim to calm immune system after massive heart attack

NCT ID NCT07380659

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment for people in shock after a severe heart attack. The therapy uses specially engineered immune cells (CAR-DC) to target a protein found in heart scar tissue, aiming to calm the immune response. The study will enroll 18 patients and primarily check for safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
genetically modified immune cells (CAR-DC) targeting a heart scar protein
What this could lead to
If it works, this could point toward a new way to reduce inflammation and improve recovery after a severe heart attack.
What could go wrong
This is a very early, small safety trial (18 people). The therapy is new and unproven; it may not help or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION WITH CARDIOGENIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction cardiogenic shock Shock, Cardiogenic ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOGENIC SHOCK CARDIOGENIC SHOCK POST MYOCARDIAL INFARCTION STEMI - ST ELEVATION MYOCARDIAL INFARCTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310009, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.